发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Update on long- and short-acting contraceptive methods. 长效和短效避孕方法的最新情况。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.023
Emma Mason, Kirsten Black
{"title":"Update on long- and short-acting contraceptive methods.","authors":"Emma Mason, Kirsten Black","doi":"10.18773/austprescr.2025.023","DOIUrl":"10.18773/austprescr.2025.023","url":null,"abstract":"<p><p>Long-acting reversible contraceptive methods, including the contraceptive implant and intrauterine devices, are highly effective and cost-effective options for women who have no specific contraindications. Long-acting reversible contraceptives are more effective at reducing unintended pregnancy than short-acting contraceptives. Short-acting contraceptive methods consist of combined hormonal contraception (e.g. the combined oral contraceptive pill, vaginal ring), progestogen-only pills, and the progestogen-containing contraceptive injection. Choice of contraception is based on factors such as medical eligibility (i.e. precautions, contraindications), patient preference and reproductive life stage. Counselling patients on the benefits and risks of all contraceptive methods is important for informed decision-making. Regular contraceptive review can allow for patient education and monitoring of adverse effects.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"72-81"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis: an update on topical and systemic therapies. 牛皮癣：局部和全身治疗的最新进展。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.026
Jonathan J Chan
{"title":"Psoriasis: an update on topical and systemic therapies.","authors":"Jonathan J Chan","doi":"10.18773/austprescr.2025.026","DOIUrl":"10.18773/austprescr.2025.026","url":null,"abstract":"<p><p>Psoriasis is an immune-mediated inflammatory disease with a genetic predisposition. Although manifesting predominantly as a hyperproliferative skin disorder, psoriasis is a systemic disease associated with a range of comorbidities including arthritis, cardiovascular disease and depression. Educating the patient that psoriasis is chronic and that there are possible comorbidities is paramount. Patients with a limited number of plaques and no systemic symptoms may be managed with intermittent use of topical therapies. Those with more extensive or debilitating disease may require phototherapy or systemic medicines such as methotrexate or one of the newer targeted therapies. Newer systemic therapies, including oral medicines and injectable biologics, can only be used following unsuccessful treatment with traditional therapies such as methotrexate and phototherapy. Biologic therapies for psoriasis offer the possibility of near-complete symptom resolution in people with psoriatic disease.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"87-92"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More dual labelled medicines transition to sole names. 更多的双重标签药物转变为单一名称。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.022
{"title":"More dual labelled medicines transition to sole names.","authors":"","doi":"10.18773/austprescr.2025.022","DOIUrl":"10.18773/austprescr.2025.022","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"106"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spesolimab for generalised pustular psoriasis. Spesolimab治疗全身性脓疱性银屑病。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.025
{"title":"Spesolimab for generalised pustular psoriasis.","authors":"","doi":"10.18773/austprescr.2025.025","DOIUrl":"10.18773/austprescr.2025.025","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"109-110"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines used in the treatment of opioid dependence. 用于治疗阿片类药物依赖的药物。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.028
Hester Hk Wilson, Jillian Kanck
{"title":"Medicines used in the treatment of opioid dependence.","authors":"Hester Hk Wilson, Jillian Kanck","doi":"10.18773/austprescr.2025.028","DOIUrl":"10.18773/austprescr.2025.028","url":null,"abstract":"<p><p>Opioid dependence is a chronic condition that can lead to significant harm if left untreated. People who experience opioid dependence and the treatments themselves are highly stigmatised. Person-centred trauma-informed services are critical to therapeutic engagement and effectiveness. Buprenorphine and methadone are highly effective, evidence-based medicines for opioid dependence. In recent years, long-acting injectable buprenorphine has emerged as a safe and effective treatment option, offering flexible weekly or monthly dosing. The long-term treatment of opioid dependence can be undertaken in primary care settings. General practitioner and nurse practitioner prescribing, and community pharmacist dispensing, are essential for ongoing care. Australian jurisdictions have differing regulations that guide the prescribing of medicines for opioid dependence. Health professionals should be familiar with their local jurisdiction's guidelines as well as the national guidelines. Drug and alcohol telephone services are available in each jurisdiction and can provide advice to health professionals.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"98-105"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication). 西马鲁肽用于超重或无糖尿病的肥胖人群心血管风险降低（新适应症）。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.024
{"title":"Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication).","authors":"","doi":"10.18773/austprescr.2025.024","DOIUrl":"10.18773/austprescr.2025.024","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"107-108"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Male and female pattern hair loss. 男性和女性的脱发模式。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.020
Laxmi Iyengar, Jane Li
{"title":"Male and female pattern hair loss.","authors":"Laxmi Iyengar, Jane Li","doi":"10.18773/austprescr.2025.020","DOIUrl":"10.18773/austprescr.2025.020","url":null,"abstract":"<p><p>Androgenetic alopecia, commonly referred to as male or female pattern hair loss, is a prevalent condition encountered in clinical practice. It is important to identify potential underlying causes and differentiate it from other forms of hair loss, which may require referral to a dermatologist for management. Pharmacological treatments for female pattern hair loss include minoxidil (topical and oral) and antiandrogens such as spironolactone. For male pattern hair loss, minoxidil and 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride) can be used. Combination therapy is commonly employed, with clinical improvement typically requiring a minimum of 6 months. Supplements and other treatments have varying levels of evidence, and counselling is important to help patients make informed decisions about their management.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"93-97"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Talazoparib for prostate cancer and breast cancer. Talazoparib治疗前列腺癌和乳腺癌。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.027
{"title":"Talazoparib for prostate cancer and breast cancer.","authors":"","doi":"10.18773/austprescr.2025.027","DOIUrl":"10.18773/austprescr.2025.027","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"111-113"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using pharmacogenomics to personalise drug therapy: which drugs, when and how. 使用药物基因组学来个性化药物治疗：哪些药物，何时以及如何使用。
IF 3.4
Australian Prescriber Pub Date : 2025-06-01 DOI: 10.18773/austprescr.2025.021
Sophie L Stocker, Thomas M Polasek
{"title":"Using pharmacogenomics to personalise drug therapy: which drugs, when and how.","authors":"Sophie L Stocker, Thomas M Polasek","doi":"10.18773/austprescr.2025.021","DOIUrl":"10.18773/austprescr.2025.021","url":null,"abstract":"<p><p>Pharmacogenomic testing provides information on whether a patient possesses gene variants that can influence drug exposure or response. It can be used as part of clinical decision-making to personalise drug therapy. Pharmacogenomic testing can help identify patients at higher risk of serious adverse drug reactions or therapeutic failure, and sometimes it can explain unexpected adverse effects or poor efficacy in patients already on drug therapy. As drug responses are influenced by many factors, pharmacogenomic test results must always be interpreted in the clinical context of the patient. At the time of writing, tests for thiopurine methyltransferase (TPMT) (azathioprine, mercaptopurine, thioguanine) and human leucocyte antigen B*57:01 (abacavir) are Medicare-rebated. Pharmacogenomic testing is also recommended for several other drugs, such as allopurinol and clopidogrel, but these do not currently attract a Medicare rebate.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 3","pages":"82-86"},"PeriodicalIF":3.4,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Icosapent ethyl and gastrointestinal bleeds. 乙基戊二醇和胃肠道出血。
IF 3.4
Australian Prescriber Pub Date : 2025-04-01 DOI: 10.18773/austprescr.2025.014
Stephanie Ternel
{"title":"Icosapent ethyl and gastrointestinal bleeds.","authors":"Stephanie Ternel","doi":"10.18773/austprescr.2025.014","DOIUrl":"https://doi.org/10.18773/austprescr.2025.014","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 2","pages":"62"},"PeriodicalIF":3.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信